222 related articles for article (PubMed ID: 14673050)
1. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Markman M; Zanotti K; Peterson G; Kulp B; Webster K; Belinson J
J Clin Oncol; 2003 Dec; 21(24):4611-4. PubMed ID: 14673050
[TBL] [Abstract][Full Text] [Related]
2. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin desensitization.
Choi J; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):137-41. PubMed ID: 15328672
[TBL] [Abstract][Full Text] [Related]
5. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
Syrigou E; Makrilia N; Vassias A; Nikolaidis I; Xyla V; Manolopoulos L; Syrigos K
Anticancer Drugs; 2010 Mar; 21(3):333-8. PubMed ID: 20038831
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.
Leguy-Seguin V; Jolimoy G; Coudert B; Pernot C; Dalac S; Vabres P; Collet E
J Allergy Clin Immunol; 2007 Mar; 119(3):726-30. PubMed ID: 17258305
[TBL] [Abstract][Full Text] [Related]
7. Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies.
McAlpine JN; Kelly MG; O'malley DM; Azodi M; Coombe K; Schwartz PE; Rutherford TJ
Gynecol Oncol; 2006 Oct; 103(1):288-92. PubMed ID: 16647749
[TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
10. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
11. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2005 Nov; 99(2):393-9. PubMed ID: 16054201
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.
Zanotti KM; Rybicki LA; Kennedy AW; Belinson JL; Webster KD; Kulp B; Peterson G; Markman M
J Clin Oncol; 2001 Jun; 19(12):3126-9. PubMed ID: 11408510
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin hypersensitivity reactions.
Winkeljohn D; Polovich M
Clin J Oncol Nurs; 2006 Oct; 10(5):595-8. PubMed ID: 17063613
[TBL] [Abstract][Full Text] [Related]
14. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.
Callahan MB; Lachance JA; Stone RL; Kelsey J; Rice LW; Jazaeri AA
Am J Obstet Gynecol; 2007 Aug; 197(2):199.e1-4; discussion 199.e4-5. PubMed ID: 17689649
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies.
Tamiya M; Kuhara H; Hirashima T; Kondo Y; Santo M; Morishita N; Suzuki H; Sasada S; Okamoto N; Kobayashi M; Kawase I
Anticancer Res; 2011 Dec; 31(12):4525-8. PubMed ID: 22199326
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Markman M; Hsieh F; Zanotti K; Webster K; Peterson G; Kulp B; Spicel A; Belinson J
J Cancer Res Clin Oncol; 2004 Jan; 130(1):25-8. PubMed ID: 14564516
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.
Lafay-Cousin L; Sung L; Carret AS; Hukin J; Wilson B; Johnston DL; Zelcer S; Silva M; Odame I; Mpofu C; Strother D; Bouffet E
Cancer; 2008 Feb; 112(4):892-9. PubMed ID: 18098210
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin hypersensitivity and desensitization in an infant.
Montiel Herrera JM; Góngora-Melendez MA; Pineda-Maldonado ML; Medina-Sanson A; Del Rio Chivardi JM; Del Río-Navarro BE; Rosas-Vargas MA
Ther Drug Monit; 2010 Aug; 32(4):525-8. PubMed ID: 20463633
[TBL] [Abstract][Full Text] [Related]
19. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
Dizon DS; Sabbatini PJ; Aghajanian C; Hensley ML; Spriggs DR
Gynecol Oncol; 2002 Mar; 84(3):378-82. PubMed ID: 11855873
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of hypersensitivity reactions to carboplatin.
Markman M; Kennedy A; Webster K; Elson P; Peterson G; Kulp B; Belinson J
J Clin Oncol; 1999 Apr; 17(4):1141. PubMed ID: 10561172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]